
Zachary P. Best
Examiner (ID: 15164)
| Most Active Art Unit | 1727 |
| Art Unit(s) | 1727, 4191, OPQA, 1795 |
| Total Applications | 483 |
| Issued Applications | 298 |
| Pending Applications | 1 |
| Abandoned Applications | 185 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20567127
[patent_doc_number] => 20260061045
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-03-05
[patent_title] => METHOD FOR PREVENTION AND TREATMENT OF VIRAL DISEASE
[patent_app_type] => utility
[patent_app_number] => 19/320827
[patent_app_country] => US
[patent_app_date] => 2025-09-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14639
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19320827
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/320827 | METHOD FOR PREVENTION AND TREATMENT OF VIRAL DISEASE | Sep 4, 2025 | Pending |
Array
(
[id] => 20511313
[patent_doc_number] => 20260035414
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-02-05
[patent_title] => HERV-K (HML-2) ENV ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 19/287448
[patent_app_country] => US
[patent_app_date] => 2025-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34810
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19287448
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/287448 | HERV-K (HML-2) ENV ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | Jul 30, 2025 | Pending |
Array
(
[id] => 20288615
[patent_doc_number] => 20250313858
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-10-09
[patent_title] => SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES
[patent_app_type] => utility
[patent_app_number] => 19/183257
[patent_app_country] => US
[patent_app_date] => 2025-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31878
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19183257
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/183257 | Synthetic modified vaccinia Ankara (SMVA) based coronavirus vaccines | Apr 17, 2025 | Issued |
Array
(
[id] => 20316734
[patent_doc_number] => 12455280
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-28
[patent_title] => Ligand discovery and gene delivery via retroviral surface display
[patent_app_type] => utility
[patent_app_number] => 19/014949
[patent_app_country] => US
[patent_app_date] => 2025-01-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 34
[patent_no_of_words] => 11286
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19014949
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/014949 | Ligand discovery and gene delivery via retroviral surface display | Jan 8, 2025 | Issued |
Array
(
[id] => 20116018
[patent_doc_number] => 12365707
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-22
[patent_title] => Methods and products for genetic engineering
[patent_app_type] => utility
[patent_app_number] => 18/742986
[patent_app_country] => US
[patent_app_date] => 2024-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 34
[patent_no_of_words] => 17107
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18742986
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/742986 | Methods and products for genetic engineering | Jun 12, 2024 | Issued |
Array
(
[id] => 19570412
[patent_doc_number] => 20240374704
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-14
[patent_title] => UNGULATE-DERIVED POLYCLONAL IMMUNOGLOBULIN SPECIFIC FOR CORONAVIRUS PROTEIN AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/637145
[patent_app_country] => US
[patent_app_date] => 2024-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17966
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18637145
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/637145 | UNGULATE-DERIVED POLYCLONAL IMMUNOGLOBULIN SPECIFIC FOR CORONAVIRUS PROTEIN AND USES THEREOF | Apr 15, 2024 | Pending |
Array
(
[id] => 19512124
[patent_doc_number] => 20240343810
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
[patent_app_type] => utility
[patent_app_number] => 18/616452
[patent_app_country] => US
[patent_app_date] => 2024-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 104704
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18616452
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/616452 | MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY | Mar 25, 2024 | Pending |
Array
(
[id] => 19202836
[patent_doc_number] => 20240174735
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-30
[patent_title] => ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION
[patent_app_type] => utility
[patent_app_number] => 18/440344
[patent_app_country] => US
[patent_app_date] => 2024-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44613
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 151
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18440344
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/440344 | Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection | Feb 12, 2024 | Issued |
Array
(
[id] => 19216339
[patent_doc_number] => 20240181043
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-06
[patent_title] => IDENTIFYING PATIENT POPULATIONS VULNERABLE TO VIRAL INFECTION AND METHODS OF INDUCING HETEROLOGOUS IMMUNITY IN SAME
[patent_app_type] => utility
[patent_app_number] => 18/440735
[patent_app_country] => US
[patent_app_date] => 2024-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12123
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18440735
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/440735 | IDENTIFYING PATIENT POPULATIONS VULNERABLE TO VIRAL INFECTION AND METHODS OF INDUCING HETEROLOGOUS IMMUNITY IN SAME | Feb 12, 2024 | Pending |
Array
(
[id] => 20158207
[patent_doc_number] => 12384819
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-12
[patent_title] => Modified cytomegalovirus proteins and stabilized complexes
[patent_app_type] => utility
[patent_app_number] => 18/435026
[patent_app_country] => US
[patent_app_date] => 2024-02-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 46021
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18435026
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/435026 | Modified cytomegalovirus proteins and stabilized complexes | Feb 6, 2024 | Issued |
Array
(
[id] => 19554966
[patent_doc_number] => 20240366758
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => FORMULATIONS OF ANTIBODY MOLECULES TO DENGUE VIRUS
[patent_app_type] => utility
[patent_app_number] => 18/420532
[patent_app_country] => US
[patent_app_date] => 2024-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47478
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18420532
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/420532 | FORMULATIONS OF ANTIBODY MOLECULES TO DENGUE VIRUS | Jan 22, 2024 | Pending |
Array
(
[id] => 19752842
[patent_doc_number] => 20250041407
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-06
[patent_title] => VARICELLA ZOSTER VIRUS (VZV) VACCINE
[patent_app_type] => utility
[patent_app_number] => 18/416835
[patent_app_country] => US
[patent_app_date] => 2024-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 78047
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18416835
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/416835 | VARICELLA ZOSTER VIRUS (VZV) VACCINE | Jan 17, 2024 | Pending |
Array
(
[id] => 19127626
[patent_doc_number] => 20240132979
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => Primers and Probes and Reagent Kit for Synchronous Detection of CymMV, ORSV, and CymRSV, and Applications Thereof
[patent_app_type] => utility
[patent_app_number] => 18/401631
[patent_app_country] => US
[patent_app_date] => 2024-01-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6218
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 98
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18401631
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/401631 | Primers and Probes and Reagent Kit for Synchronous Detection of CymMV, ORSV, and CymRSV, and Applications Thereof | Dec 31, 2023 | Pending |
Array
(
[id] => 19343649
[patent_doc_number] => 20240252612
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => IMMUNOGENIC COMPOSITIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/533167
[patent_app_country] => US
[patent_app_date] => 2023-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 104158
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18533167
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/533167 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | Dec 6, 2023 | Pending |
Array
(
[id] => 19083139
[patent_doc_number] => 20240109940
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-04
[patent_title] => METHODS AND PRODUCTS FOR GENETIC ENGINEERING
[patent_app_type] => utility
[patent_app_number] => 18/518304
[patent_app_country] => US
[patent_app_date] => 2023-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21029
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18518304
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/518304 | Methods and products for genetic engineering | Nov 21, 2023 | Issued |
Array
(
[id] => 20437486
[patent_doc_number] => 12508307
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-30
[patent_title] => Genetically modified anti-third party central memory T cells and use of same in immunotherapy
[patent_app_type] => utility
[patent_app_number] => 18/515358
[patent_app_country] => US
[patent_app_date] => 2023-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 13
[patent_no_of_words] => 23484
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 146
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18515358
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/515358 | Genetically modified anti-third party central memory T cells and use of same in immunotherapy | Nov 20, 2023 | Issued |
Array
(
[id] => 19035486
[patent_doc_number] => 20240085301
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => ANALYTICAL ULTRACENTRIFUGATION FOR CHARACTERIZATION OF RECOMBINANT VIRAL PARTICLES
[patent_app_type] => utility
[patent_app_number] => 18/513970
[patent_app_country] => US
[patent_app_date] => 2023-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28435
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18513970
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/513970 | Analytical ultracentrifugation for characterization of recombinant viral particles | Nov 19, 2023 | Issued |
Array
(
[id] => 19034513
[patent_doc_number] => 20240084328
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => METHODS FOR ANALYSIS OF VIRAL CAPSID PROTEIN COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 18/509781
[patent_app_country] => US
[patent_app_date] => 2023-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9927
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18509781
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/509781 | Methods for analysis of viral capsid protein composition | Nov 14, 2023 | Issued |
Array
(
[id] => 19242896
[patent_doc_number] => 12013326
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-18
[patent_title] => Analytical ultracentrifugation for characterization of recombinant viral particles
[patent_app_type] => utility
[patent_app_number] => 18/506853
[patent_app_country] => US
[patent_app_date] => 2023-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 33
[patent_no_of_words] => 28416
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 166
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18506853
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/506853 | Analytical ultracentrifugation for characterization of recombinant viral particles | Nov 9, 2023 | Issued |
Array
(
[id] => 19065727
[patent_doc_number] => 20240100153
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE
[patent_app_type] => utility
[patent_app_number] => 18/506578
[patent_app_country] => US
[patent_app_date] => 2023-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44394
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18506578
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/506578 | Human cytomegalovirus gB polypeptide | Nov 9, 2023 | Issued |